TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study (TIGER Meso)

NovoCure logo

NovoCure

Status

Enrolling

Conditions

Pleural Mesothelioma

Treatments

Device: TTFields

Study type

Observational

Funder types

Industry

Identifiers

NCT05538806
CIP-RS-001

Details and patient eligibility

About

The purpose of this post-authorisation medical device study is to obtain real life data on the use of Tumor Treating Fields (TTFields) in patients with pleural mesothelioma in routine clinical care. Patients with pleural mesothelioma and clinical indication for TTFields treatment will be enrolled in the study after signing Informed consent to use their data and process it centrally for research purposes. The clinical indication for TTFields is one of the inclusion criteria and is defined prior to inclusion by the treating physician.

Enrollment

198 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • ≥ 18 years of age
  • Histologically confirmed pleural mesothelioma without any option of curative resection
  • Planned treatment with NovoTTF-200T System according to IFU and medical guidelines
  • Life expectancy more than 3 months at day of enrollment
  • Signed informed consent for use and processing of data

Exclusion criteria

• Previous treatment with NovoTTF-200T for more than 1 week at day of enrollment

Trial design

198 participants in 1 patient group

Group 1
Description:
all patients will receive routine clinical care and TTFields
Treatment:
Device: TTFields

Trial contacts and locations

16

Loading...

Central trial contact

Giovanni Ceresoli

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems